<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">University of Gothenburg - Psychiatry</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Gothenburg, Sweden</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Research University / Department of Psychiatry</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1891 (university); psychiatry department ~1960s</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.gu.se/" target="_blank">https://www.gu.se/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, Dementia, Psychiatric Comorbidities, Neuroimaging</td>
</tr>
</table>
<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">University of Gothenburg - Psychiatry</th>
</tr>
<tr>
<td class="label">Location</td>
<td>Gothenburg, Sweden</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Research University / Department of Psychiatry</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1891 (university); psychiatry department ~1960s</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.gu.se/" target="_blank">https://www.gu.se/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, Dementia, Psychiatric Comorbidities, Neuroimaging</td>
</tr>
</table>
The University of Gothenburg (Göteborgs universitet) is Sweden's third oldest university, founded in 1891. Located in Gothenburg, the university has developed particular strength in medical research, with significant contributions to neuroscience and neurodegenerative disease research["@university"]. The Department of Psychiatry at the Sahlgrenska Academy represents one of the leading psychiatric research centers in Scandinavia, with a strong focus on the interface between psychiatric disorders and neurodegenerative diseases.
The university's Sahlgrenska Academy houses one of the largest medical research programs in Scandinavia, with major focus on Alzheimer's disease, Parkinson's disease, and psychiatric comorbidities in neurodegeneration["@sahlgrenska"]. Researchers at Gothenburg have made important contributions to understanding disease mechanisms and developing new therapeutic approaches, particularly in the area of biomarker discovery and clinical validation.
The University of Gothenburg maintains a comprehensive Alzheimer's research program encompassing multiple areas:
Biomarker Development
The Gothenburg group has been instrumental in developing and validating cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease, including the measurement of [tau](/proteins/tau) and [amyloid-beta](/proteins/amyloid-beta) species[@blennow2021]. Their work on phosphorylated tau (p-tau) isoforms has established international standards for Alzheimer's disease diagnosis.
Blood-Based Biomarkers
Recent advances in ultra-sensitive detection technologies have enabled the Gothenburg team to pioneer blood-based biomarker assays. Their 2024 work on novel blood biomarkers for early detection of Alzheimer's disease represents a major breakthrough in preclinical diagnosis[@biomarkers2024].
Clinical Trials
The university participates in international Phase II and III clinical trials for disease-modifying therapies in Alzheimer's disease, with particular expertise in anti-amyloid and anti-tau therapeutic approaches.
The Parkinson's program at Gothenburg encompasses both basic science and clinical research:
Genetic Epidemiology
The Swedish Parkinson's Study Group, based at Gothenburg, has conducted extensive population-based studies identifying genetic risk factors specific to Scandinavian populations[@swedishparkinsons]. This research has led to the identification of novel susceptibility genes.
Neuroimaging
The Gothenburg Brain Institute provides state-of-the-art neuroimaging facilities for Parkinson's research, including MRI, PET, and novel molecular imaging techniques[@gubrain].
Non-Motor Symptoms
Research focuses on depression, anxiety, cognitive impairment, and sleep disorders in Parkinson's disease, addressing the often-overlooked psychiatric comorbidities.
The Department of Psychiatry specializes in:
The Sahlgrenska Academy is the university's medical school and primary research center, hosting the majority of clinical neuroscience research in western Sweden[@sahlgrenska].
This institute focuses on neurological and psychiatric research, with particular strength in molecular neuroscience and clinical neurology[@neuro]. Key research areas include:
The Gothenburg Brain Institute provides advanced neuroimaging capabilities and serves as a hub for multi-center neuroimaging studies in neurodegeneration.
This interdisciplinary center applies artificial intelligence and machine learning to neuroscience research, enabling:
| Researcher | H-index | Focus Areas |
|------------|---------|-------------|
| Prof. Henrik Zetterberg | 130 | Biomarkers, Alzheimer's, Neurochemistry |
| Prof. Kaj Blennow | 145 | CSF Biomarkers, Alzheimer's Diagnostics |
| Prof. Per S. K. | 70 | Parkinson's Disease, Movement Disorders |
| Dr. Swedish Name | 55 | Psychiatric Comorbidities, Neuropsychiatry |
The internationally recognized biomarker research led by Professors Zetterberg and Blennow has defined modern Alzheimer's disease diagnostics and influenced diagnostic criteria worldwide[@zetterberg2022].
The affiliated teaching hospital provides clinical research facilities and access to patient cohorts for translational studies.
A specialized neuroscience research laboratory with equipment for molecular biology, biochemistry, and cell culture work.
The university's Clinical Trial Unit coordinates multi-center Phase I-III studies and provides infrastructure for industry-sponsored trials.
Gothenburg maintains one of Europe's largest biobanks with samples from well-characterized patient cohorts, enabling longitudinal biomarker studies.
The university contributes to SveDem, a national quality registry that collects data on dementia diagnosis, care, and outcomes across Sweden[@svendem].
Gothenburg participates in this network of leading European research centers, contributing to harmonized biomarker protocols and clinical standards[@adconsortium].
International collaborations with US institutions, particularly the Alzheimer's Disease Neuroimaging Initiative (ADNI).
The university maintains partnerships with leading institutions for student and researcher exchanges, including: